CN116920047A - 一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 - Google Patents
一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 Download PDFInfo
- Publication number
- CN116920047A CN116920047A CN202310636445.8A CN202310636445A CN116920047A CN 116920047 A CN116920047 A CN 116920047A CN 202310636445 A CN202310636445 A CN 202310636445A CN 116920047 A CN116920047 A CN 116920047A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- compound composition
- medicine compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 208000037891 myocardial injury Diseases 0.000 title claims abstract description 18
- 241001061264 Astragalus Species 0.000 claims abstract description 12
- 235000006533 astragalus Nutrition 0.000 claims abstract description 12
- 210000004233 talus Anatomy 0.000 claims abstract description 12
- 241000756943 Codonopsis Species 0.000 claims abstract description 7
- 240000002948 Ophiopogon intermedius Species 0.000 claims abstract description 6
- 241000756042 Polygonatum Species 0.000 claims abstract description 6
- 235000008737 Polygonatum biflorum Nutrition 0.000 claims abstract description 6
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 6
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 6
- 240000007164 Salvia officinalis Species 0.000 claims abstract description 6
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 6
- 235000005412 red sage Nutrition 0.000 claims abstract description 6
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000002244 precipitate Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 238000000465 moulding Methods 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 abstract description 13
- 206010008479 Chest Pain Diseases 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 210000004165 myocardium Anatomy 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 7
- 208000029549 Muscle injury Diseases 0.000 abstract description 6
- 208000008454 Hyperhidrosis Diseases 0.000 abstract description 5
- 208000006083 Hypokinesia Diseases 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 5
- 230000008506 pathogenesis Effects 0.000 abstract description 5
- 230000037315 hyperhidrosis Effects 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 230000006378 damage Effects 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 43
- 208000024891 symptom Diseases 0.000 description 13
- 230000002107 myocardial effect Effects 0.000 description 9
- 206010037660 Pyrexia Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 102000004890 Interleukin-8 Human genes 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 208000009525 Myocarditis Diseases 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 101100537532 Rattus norvegicus Tnni3 gene Proteins 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 229940096397 interleukin-8 Drugs 0.000 description 4
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 206010047470 viral myocarditis Diseases 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- UHWVSEOVJBQKBE-UHFFFAOYSA-N Trimetazidine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCNCC1 UHWVSEOVJBQKBE-UHFFFAOYSA-N 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108091022862 fatty acid binding Proteins 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000008862 fructus schizandrae, radix ginseng, radix ophiopogonis drug combination Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229960001177 trimetazidine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,所述中药复方组合物的有效成分组成及其质量份数为:红景天15~30份,生黄芪15~60份,炙黄芪15~60份,丹参15~30份,党参15~30份,麦冬20~60份,五味子6~10份,玉竹15~30份。本发明采用上述一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,用于治疗新型冠状病毒感染相关心肌损伤气阴耗伤、心脉瘀阻证,针对胸闷、心悸、多汗、乏力诸证的基本病机,具有益气养阴,活血养心功效。
Description
技术领域
本发明属于中药复方组合物,尤其涉及一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法。
背景技术
目前COVID-19是如何引起心肌损伤,又是如何进展为心肌炎,其相关机制及病理生理改变目前仍未知。COVID-19引起心脏损伤的机制可能多方面的,可能不仅包括内皮炎或心肌炎,还包括由于氧供需不匹配、微血管血栓、全身性过度炎症反应和心肌缺血引起的心肌损伤。COVID-19相关心肌炎的预防和治疗仍是一大挑战,现代医学治疗以休息、对症支持处理为主,尚缺乏针对性治疗措施,是亟需开展研究的临床难点,而中医药在防治病毒性心肌炎方面已经显示出较大的优势。
病毒性心肌炎在古代文献中虽无明确记载,但历代文献中可散见对本病的论述,依据临床特点及发病原因等,中医学常将其归属于“温病”、“心悸”、“怔忡”、“胸痹”等范畴,有古籍记载可知,气阴两虚为发病之本,治法重在健脾补气,滋养心体,养阴活血。使肺脾气盛,营卫充沛,御邪有力,血运畅行,为治法之关键。
发明内容
本发明的目的是针对新型冠状病毒感染相关心肌损伤的临床防治难点,提供一种对新型冠状病毒感染相关心肌损伤有辅助治疗作用,具有益气养阴,活血养心功效的中药复方组合物及其制备方法。
为了实现上述目的,本发明提供了一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,所述中药复方组合物的有效成分组成及其质量份数为:红景天15~30份,生黄芪15~60份,炙黄芪15~60份,丹参15~30份,党参15~30份,麦冬20~60份,五味子6~10份,玉竹15~30份。
优选的,所述中药复方组合物的制备方法包括以下步骤:(1)取红景天、生黄芪、炙黄芪、丹参、党参、麦冬、五味子、玉竹饮片,加水煎煮二次,合并煎液;(2)过滤煎液,并浓缩滤液,加入乙醇进行醇沉处理,滤去沉淀物,滤液回收并浓缩,得浸膏;(3)取步骤(2)得到的浸膏,与药用载体制备成型。
优选的,步骤(1)中煎煮时间为每次1~2小时。
优选的,步骤(2)中乙醇的体积浓度为85%。
优选的,步骤(2)中浓缩温度为80℃。
优选的,步骤(2)中浓缩至相对密度为1.30~1.36。
优选的,浸膏与药用载体制备成膏剂、口服液、颗粒剂、胶囊剂、片剂或滴丸剂。
因此,本发明采用上述的一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,用于治疗新型冠状病毒感染相关心肌损伤气阴耗伤、心脉瘀阻证,针对胸闷、心悸、多汗、乏力诸证的基本病机,具有益气养阴,活血养心功效。
下面通过实施例,对本发明的技术方案做进一步的详细描述。
具体实施方式
以下通过实施例对本发明的技术方案作进一步说明。
除非另外定义,本发明使用的技术术语或者科学术语应当为本发明所属领域内具有一般技能的人士所理解的通常意义。
实施例一
一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,按质量份数包括以下中药饮片成分:红景天15~30份,生黄芪15~60份,炙黄芪15~60份,丹参15~30份,党参15~30份,麦冬20~60份,五味子6~10份,玉竹15~30份。
该中药复方组合物的制备方法:(1)按以上所述的质量份数取红景天、生黄芪、炙黄芪、丹参、党参、麦冬、五味子、玉竹饮片,加水煎煮二次,每次1~2小时,合并煎液;(2)过滤煎液,浓缩滤液,加入体积浓度为85%乙醇进行醇沉处理,滤去沉淀物,滤液回收并80℃浓缩至相对密度1.30~1.36,得浸膏;(3)取步骤(2)得到的浸膏,与药学上可接受的载体制备成膏剂、口服液、颗粒剂、胶囊剂、片剂或滴丸剂型的药物。
以下通过临床试验、阐明本发明所述用于治疗一种新型冠状病毒感染相关心肌损伤的中药复方组合物的治疗效果。
实施例二
实验招募了52位符合诊断和入组标准的患者,以上患者年龄≥18岁,均为实验室确诊或临床确诊的新型冠状病毒感染患者,心肌肌钙蛋白呈阳性,具有心悸、发热、胸闷、乏力、多汗、小便赤、大便干结、舌红少苔、脉细数等症状。
实验方法:
(1)病例分组:将52例患者按照随机数字表法分为对照组和中药组。每组各26例。对照组男11例,女15例,年龄16~52岁,平均年龄(42.43±8.52)岁,病程4~27d,平均病程(13.44±6.72)d;中药组男14例,女12例,年龄17~62岁,平均年龄(44.36±7.94)岁,病程5~32d,平均病程(14.89±8.22)d。两组患者基线资料对比P>0.05,具有可比性。
(2)治疗方案:两组患者均按照《新型冠状病毒感染诊疗方案(试行第十版)》和《中医内科常见病诊疗指南(西医疾病部分):病毒性心肌炎》给予基础的治疗。
对照组患者常规营养心肌治疗:给予维生素C片口服100mg/次,3次/d;辅酶Q10片,每次10mg,每天3次,饭后服用;盐酸曲美他嗪片,每次20mg,每天3次,餐后服用。连续治疗14天。重症者另予地塞米松磷酸钠注射液,每次20mg,加入5%葡萄糖注射液100mL中静脉滴注,每天1次,连续14d。
中药组患者在对照组基础上给予给予“红芪参脉饮”中药汤剂治疗,方剂组成为:红景天15g,生黄芪15g,炙黄芪15g,丹参15g,党参15g,麦冬20g份,五味子6g,玉竹15g。用500mL水将药物浸泡后,水煎30min,早晚各服用1次,1剂/d,连续治疗14天。
治疗期间患者如有发热症状,立即物理降温,必要时给予布洛芬或对乙酰氨基酚对症治疗。
实施例三
(1)疗效评价指标
①治疗效果对比
根据患者症状、体征及实验室检查结果评估患者治疗效果:患者心肌酶谱各指标正常、心电图正常,心悸、发热、胸闷、咽痛等症状消失,即为痊愈;患者心肌酶谱各指标正常、心电图大致正常,心悸、发热、胸闷、咽痛等缓解或偶有发生,即为有效;患者心肌酶、心电图异常,心悸、发热、胸闷、咽痛未缓解和改善,即为无效。总有效率=(痊愈+有效)/总例数×100%。
②中医症状评分对比
依据《中药新药临床研究指导原则》,对两组患者治疗前后心悸、发热、胸闷、咽痛等症状进行评分量化。
③心肌酶谱对比
所有患者治疗前后于清晨抽取空腹静脉血5mL,使用离心机3000r/min离心10min,取上层血清。全自动生化分析仪测定血清磷酸肌酸激酶(CK)、磷酸肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)水平;酶联免疫吸附法测定血清肌钙蛋白-I(cTnI)和心型游离脂肪酸结合蛋白(H-FABP)水平。
④炎症指标对比
采取酶联免疫吸附法测定两组患者治疗前后白介素6(IL-6)、白介素8(IL-8)、肿瘤坏死因子α(TNF-α)水平。
(2)统计分析
应用SPSS21.0软件对数据进行统计学分析,计量资料符合正态分布,以均数±标准差表示,组间均数比较采用t检验,计数资料比较采用χ2检验,以P<0.05为差异有统计学意义。
因此,本发明采用上述一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,用于治疗新型冠状病毒感染相关心肌损伤气阴耗伤、心脉瘀阻证,针对胸闷、心悸、多汗、乏力诸证的基本病机,具有益气养阴,活血养心功效。
实施例四
实验结果:
(1)两组总体临床疗效比较:中药组有效率显著高于对照组(P<0.05),见表1。
表1两组总体疗效比较[n(%)]
(2)两组治疗前后中医症状积分变化比较:治疗前两组患者心悸、胸闷气短、乏力、自汗、发热咽痛、失眠等症状积分比较无显著性差异(P>0.05);治疗后各组积分较治疗前均下降,中药组治疗后各项症状积分均明显低于对照组(P<0.05),见表2。
表2两组治疗前后中医症状积分比较(分)
注:较对照组治疗前,*P>0.05;较治疗前,&P<0.05;较对照组治疗后,#P<0.05。
(3)两组治疗前后心肌标志物指标变化:两组患者治疗前CK-MB、cTnI心肌酶指标比较无显著性差异(P>0.05);治疗后各组患者CK-MB、cTnI心肌酶指标均下降,中药组CK-MB、cTnI心肌酶指标优于对照组(P<0.05),见表3。
表3两组治疗前后心肌标志物指标比较
注:较对照组治疗前,*P>0.05;较治疗前,&P<0.05;较对照组治疗后,#P<0.05。
(4)两组治疗前后血清炎性因子水平变化比较:治疗前,两组患者IL-6、IL-8、TNF-α水平比较无显著性差异(P>0.05);治疗后各组患者IL-6、IL-8、TNF-α水平均下降,中药组低于对照组(P<0.05),见表4。
表4两组治疗前后血清炎性因子水平变化(ng/L)
注:较对照组治疗前,*P>0.05;较治疗前,&P<0.05;较对照组治疗后,#P<0.05。
以下进一步列举典型临床案例说明本发明的效果:
患者女性,42岁,COVID-19感染后胸闷心悸乏力1周。COVID-19感染后发热、咽痛、乏力3天,体温减退后,仍有乏力,并感胸闷、心悸、失眠、多汗,舌暗红,少苔,脉细数。CK-MB16U/L,cTnI286ng/L。心电图提示频发室性期前收缩。冠状动脉CTA未见血管异常。服用“红芪参脉饮”中药复方汤剂2周后,诸症皆消,舌淡苔薄白,脉象和缓。复查CK-MB82U/L,cTnI92ng/L;心电图提示正常范围,未见室性期前收缩发作。
最后应说明的是:以上实施例仅用以说明本发明的技术方案而非对其进行限制,尽管参照较佳实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对本发明的技术方案进行修改或者等同替换,而这些修改或者等同替换亦不能使修改后的技术方案脱离本发明技术方案的精神和范围。
Claims (7)
1.一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,其特征在于,所述中药复方组合物的有效成分组成及其质量份数为:红景天15~30份,生黄芪15~60份,炙黄芪15~60份,丹参15~30份,党参15~30份,麦冬20~60份,五味子6~10份,玉竹15~30份。
2.根据权利要求1所述的一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,其特征在于,所述中药复方组合物的制备方法包括以下步骤:(1)取红景天、生黄芪、炙黄芪、丹参、党参、麦冬、五味子、玉竹饮片,加水煎煮二次,合并煎液;(2)过滤煎液,并浓缩滤液,加入乙醇进行醇沉处理,滤去沉淀物,滤液回收并浓缩,得浸膏;(3)取步骤(2)得到的浸膏,与药用载体制备成型。
3.根据权利要求2所述的一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,其特征在于:步骤(1)中煎煮时间为每次1~2小时。
4.根据权利要求2所述的一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,其特征在于:步骤(2)中乙醇的体积浓度为85%。
5.根据权利要求2所述的一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,其特征在于:步骤(2)中浓缩温度为80℃。
6.根据权利要求2所述的一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,其特征在于:步骤(2)中浓缩至相对密度为1.30~1.36。
7.根据权利要求2所述的一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法,其特征在于:浸膏与药用载体制备成膏剂、口服液、颗粒剂、胶囊剂、片剂或滴丸剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310636445.8A CN116920047B (zh) | 2023-05-31 | 一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310636445.8A CN116920047B (zh) | 2023-05-31 | 一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116920047A true CN116920047A (zh) | 2023-10-24 |
CN116920047B CN116920047B (zh) | 2024-05-28 |
Family
ID=
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998824A (zh) * | 2006-12-28 | 2007-07-18 | 龚文君 | 一种治疗病毒性心肌炎的内服中药 |
CN101164607A (zh) * | 2007-09-29 | 2008-04-23 | 李生 | 治疗心悸不适、动辄气促的中药 |
CN102670973A (zh) * | 2012-05-09 | 2012-09-19 | 成都绿迪科技有限公司 | 一种内服治疗冠心病的中药配方 |
CN108273007A (zh) * | 2018-04-04 | 2018-07-13 | 江苏省中医院 | 一种具有治疗冠心病心绞痛作用的中药复方组合物及其制备方法与应用 |
CN109125591A (zh) * | 2018-10-22 | 2019-01-04 | 首都医科大学附属北京中医医院 | 一种治疗脓毒症心衰的中药组合物及其制备方法 |
WO2022021636A1 (zh) * | 2020-07-29 | 2022-02-03 | 汕头市中医医院 | 一种健脾活络中药组合物及其应用 |
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100998824A (zh) * | 2006-12-28 | 2007-07-18 | 龚文君 | 一种治疗病毒性心肌炎的内服中药 |
CN101164607A (zh) * | 2007-09-29 | 2008-04-23 | 李生 | 治疗心悸不适、动辄气促的中药 |
CN102670973A (zh) * | 2012-05-09 | 2012-09-19 | 成都绿迪科技有限公司 | 一种内服治疗冠心病的中药配方 |
CN108273007A (zh) * | 2018-04-04 | 2018-07-13 | 江苏省中医院 | 一种具有治疗冠心病心绞痛作用的中药复方组合物及其制备方法与应用 |
CN109125591A (zh) * | 2018-10-22 | 2019-01-04 | 首都医科大学附属北京中医医院 | 一种治疗脓毒症心衰的中药组合物及其制备方法 |
WO2022021636A1 (zh) * | 2020-07-29 | 2022-02-03 | 汕头市中医医院 | 一种健脾活络中药组合物及其应用 |
Non-Patent Citations (2)
Title |
---|
国家药典委员会: "《中国人民共和国药典-临床用药须知-中药成方制剂卷(2010年版)》", 30 April 2011, 中国医药科技出版社, pages: 582 * |
张丞波,等: "益气活血方对益气活血方对急性ST段抬高型心肌梗死后心力衰竭患者心肌纤维化的影响急性ST段抬高型心肌梗死后心力衰竭患者心肌纤维化的影响", 南京中医药大学学报, vol. 39, no. 02, 28 February 2023 (2023-02-28), pages 2 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115364170B (zh) | 一种糖代谢调节剂及其制备方法和应用 | |
CN102631595B (zh) | 治疗2型糖尿病的药物及其制备方法 | |
CN110916033A (zh) | 一种降尿酸的饮料及其制备方法 | |
CN116370556B (zh) | 一种活血祛瘀、益气安神的中药组合物及其制备方法 | |
CN115252753B (zh) | 治疗失眠的中药组合物及其应用 | |
CN116920047B (zh) | 一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 | |
CN113332395B (zh) | 一种治疗2型糖尿病的中药组合物及其制备方法 | |
CN112336802B (zh) | 一种改善糖尿病糖脂代谢的中药组合物及其应用 | |
CN113209218B (zh) | 治疗儿童室性早搏的中药组合物及其应用 | |
CN116920047A (zh) | 一种新型冠状病毒感染相关心肌损伤的中药复方组合物及制备方法 | |
CN111228367A (zh) | 一种治疗小儿过敏性紫癜的中药外用洗剂及其制备方法 | |
CN111135247A (zh) | 一种治疗iv期糖尿病肾病的中药 | |
CN108653559A (zh) | 一种降血糖组合物及其应用 | |
CN108452173A (zh) | 用于治疗特发性肺纤维化的中药复方及其制备方法和应用 | |
CN114832063B (zh) | 一种具有调节血糖、血脂和/或尿酸作用的组合物 | |
CN116808162B (zh) | 一种防治胆郁痰扰型室性期前收缩的中药组合物及其应用 | |
CN114732883B (zh) | 一种健脾益胃的中药组合物及其制备方法、应用 | |
CN110755590B (zh) | 一种保心胶囊及其制备方法 | |
CN110051720B (zh) | 一种含有降真香的中药汤剂及其作为糖尿病药物的应用 | |
CN105943860A (zh) | 一种用于治疗糖尿病的药物制剂及其制备方法 | |
CN107213204B (zh) | 一种治疗糖尿病的中药复方制剂及其制备方法和应用 | |
CN114504626A (zh) | 一种用于治疗h型高血压痰瘀互结证的畲药组方 | |
CN105288410A (zh) | 一种治疗糖尿病肾病的中药组合物及其用途 | |
CN117018105A (zh) | 一种治疗糖耐量减低的中药组合物及其制备方法 | |
CN101084997B (zh) | 一种治疗心脑血管疾病的中药冻干粉针剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant |